Suraj Peri, PhD

Assistant Research Professor

Research Program

Molecular Therapeutics

Lab Overview

The goal of my research is to understand the molecular basis of cancer through the application of bioinformatics and statistical methods on the high throughput genomics data. To identify and understand the fundamental molecular cause in cancer is cumbersome. The majority of the genomic studies have used alterations in copy number, gene expression or methylation independently to describe the molecular etiology of cancer. The recurring theme of my research is to leverage the systems level understanding of complex genomic datasets through systematic integration. I collaborate with clinical and research members of two different working groups, including renal cancer and head and neck cancer.

Major projects:

Comprehensive genomic characterization of head and neck squamous cell carcinomas to identify molecular subtypes and prognostic biomarkers in laryngeal subtypes
The role of haploinsufficiency in renal cancer predisposition

Educational Background

PhD, Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark
MSc, Biotechnology, Panjab University, Chandigarh, India

Research Interests

Understanding the molecular basis of cancer using high throughput genomics data
Interrogate and interpret the molecular relationships among head and neck cancer subtypes by integrating disparate genomic data
Identify prognostic and therapeutic biomarkers in head and neck and renal cancers

Selected Publications

Sementino E, Menges CW, Kadariya Y, Peri S, Xu J, Liu Z, Wilkes RG, Cai KQ, Rauscher FJ, 3rd, Klein-Szanto AJ, Testa JR. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. Journal of cellular physiology, 2018. PubMed

Matthew EM, Yang Z, Peri S, Andrake M, Dunbrack R, Ross E, El-Deiry WS. Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling. Neoplasia (New York, NY), 20(3):244-55, 2018. PMC5849802

Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA. NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nat Commun, 8(1):1772, 2017. PMC5701248

Chen, P., Nogusa, S., Thapa, R.J., Shaller, C., Simmons, H., Peri, S., Adams, G.P., Balachandran, S. Anti-CD70 immunocytokines for exploitation of interferon-gama-induced RIP1- dependent necrosis in renal cell carcinoma. PLoS One 8(4):e61446, 2013. PMCID:PMC3629199 PubMed

Peri, S., López de Cicco, R., Santucci-Pereira, J., Slifker, M., Ross, E.A., Russo, I.H., Russo, P.A., Arslan, A.A., Belitskaya-Lévy, I., Zeleniuch-Jacquotte, A., Bordas, P., Lenner, P., Ahman, J., Afanasyeva, Y., Johansson, R., Sheriff, F., Hallmans, G., Toniolo, P., Russo. J. Defining the genomic signature of the parous breast. BMC Med. Genomics. 5(1):46., 2012. PMCID:PMC3487939 PubMed

Additional Publications

MY NCBI

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.